Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct;25(10):1117-1126.
doi: 10.1007/s11912-023-01441-1. Epub 2023 Aug 21.

Dedifferentiated Chondrosarcoma: Diagnostic Controversies and Emerging Therapeutic Targets

Marc El Beaino  1   2 , Syed T Hoda  3 , Ahmed J Eldeib  4 , Karim Masrouha  5
Affiliations
Review

Dedifferentiated Chondrosarcoma: Diagnostic Controversies and Emerging Therapeutic Targets

Marc El Beaino et al. Curr Oncol Rep. 2023 Oct.

Abstract

Purpose of review: The pathogenesis of dedifferentiated chondrosarcoma is controversial, and no genetic abnormality has consistently been identified in the disease. Focusing on the diagnostic challenges encountered in dedifferentiated chondrosarcoma, the following review aims at summarizing the tumor's active neoplastic pathways while highlighting therapeutic modalities that could potentially be explored to enhance patient survivorship.

Recent findings: Owing to the challenging examination of small needle biopsy sampling as well as the disease's overlapping morphological and immunohistochemical features with other bone and soft-tissue sarcomas, the diagnosis of dedifferentiated chondrosarcoma can be problematic. While combined doxorubicin- and cisplatin-based regimens remain the first-line systemic chemotherapy in the disease, ~50% of tumors carry EXT1/2 or IDH1/2 mutations, advancing EXT or IDH inhibitors as potential alternative therapies, respectively. Despite systemic chemotherapy, dedifferentiated chondrosarcoma remains an aggressive tumor with dismal prognosis and limited survival. A multidisciplinary collaboration across multiple cancer centers is warranted to yield an accurate diagnosis, understand the disease's underlying pathogenesis, develop adequate treatment, and improve patient survivorship.

Keywords: Dedifferentiated chondrosarcoma; EXT and IDH inhibitors; Neoplastic pathways; Survivorship; Systemic chemotherapy.

PubMed Disclaimer

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
    1. Mitchell AD, Ayoub K, Mangham DC, Grimer RJ, Carter SR, Tillman RM. Experience in the treatment of dedifferentiated chondrosarcoma. J Bone Joint Surg Br. 2000;82(1):55–61. - DOI - PubMed
    1. Bruns J, Fiedler W, Werner M, Delling G. Dedifferentiated chondrosarcoma--a fatal disease. J Cancer Res Clin Oncol. 2005;131(6):333–9. https://doi.org/10.1007/s00432-004-0648-6 . - DOI - PubMed
    1. Staals EL, Bacchini P, Bertoni F. Dedifferentiated central chondrosarcoma. Cancer. 2006;106(12):2682–91. https://doi.org/10.1002/cncr.21936 . - DOI - PubMed
    1. • Grimer RJ, Gosheger G, Taminiau A, Biau D, Matejovsky Z, Kollender Y, et al. Dedifferentiated chondrosarcoma: prognostic factors and outcome from a European group. Eur J Cancer. 2007;43(14):2060–5. https://doi.org/10.1016/j.ejca.2007.06.016 . This study highlights the poor prognosis of patients with dedifferentiated chondrosarcoma, emphasizing the lack of substantial benefit of chemotherapy and the primary role of surgery in securing negative margins. - DOI - PubMed
    1. Dhinsa BS, DeLisa M, Pollock R, Flanagan AM, Whelan J, Gregory J. Dedifferentiated chondrosarcoma demonstrating osteosarcomatous differentiation. Oncol Res Treat. 2018;41(7-8):456–60. https://doi.org/10.1159/000487803 . - DOI - PubMed

LinkOut - more resources